

Adult Studies open at Hammersmith Hospital June 2025:

REDRESS:

A multi-centre open randomised controlled trial to assess the effect of related ***haplo-donor haematopoietic stem cell transplantation versus standard of care*** (no transplant) on treatment failure at 24 month in adults with severe sickle cell disease.

FERVENT-1:

A phase 2, two-part, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy, safety, and tolerability of subcutaneously administered ***REGN7999 (TMPRSS6 inhibitor)*** in Participants with iron overload due to non-transfusion dependent Beta Thalassemia.

Hibiscus2:

A global phase 3, randomised, double blind and placebo-controlled study evaluating the efficacy and safety of ***Etavopivat (FT- 4202 – a Pyruvate Kinase Activator)*** in adults with sickle cell disease. The study has a 52-week double blind period, with a 2:1 randomisation (Etavopivat vs Placebo).

Improving Black Health Outcomes (IBHO) NIHR BioResource:

This new research initiative is dedicated to studying health conditions that disproportionately affect people from Black communities in the UK, such as sickle cell disease and thalassemia. This observational study invites individuals from Black ethnic backgrounds to participate in research aimed at improving our understanding of how these conditions might develop and specifically affect those from Black communities.

For more information about any of these studies, please [email our team](#).